FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523348044> ?p ?o ?g. }

• W2523348044 endingPage "8142" @default.
• W2523348044 startingPage "8142" @default.
• W2523348044 abstract "8142 Background: In a recently published trial, the majority of MM pts (71.6%) who were mobilized with plerixafor plus G prior to autoT, collected > 6 × 106CD34+ cells/kg in ≤ 2 apheresis procedures, vs. 34.4% of pts who were mobilized with G and placebo (DiPersio et al, Blood 113 (23):5720-5726, 2009). We set out to assess the efficacy of Cy plus G as mobilization therapy in a similar pt population, treated at the City of Hope National Medical Center. Methods: 121 MM pts were treated on sequential tandem autoT protocols. Pts received 1.5 g/m2 of Cy followed by G at 10 microgram/kg, daily through completion of their apheresis procedures. Pts underwent consecutive leukapheresis starting on day 10 and continued until a minimum of 4 × 106 CD34+ cells/kg (up to 10 × 106 CD34+ cells/kg) were collected. Results: The median age was 54.4 years (range, 29.7-66.1). Pts were mobilized within 7.4 months from their diagnosis of MM (range, 1.3-55.3), following a median of 2 prior treatment regimens (1-8). Twenty-four percent of pts received prior radiation. The median number of days to collect 4 × 106 CD34+ cells/kg, and 6 × 106 CD34+ cells/kg were 1 (1-16), and 2 (1-16). The cumulative total for CD34+ cells/kg collected was 9.98 × 106 (2.55-35.79), requiring 3 aphereses (1-16). Neutrophil engraftment was reached in 11 days (1-16) after first, and 10 days (8-43) after the second autoT. Platelet independence was achieved by day 13 (0-71) and 12 (0-44), after the first and second autoTs. Patients who have undergone apheresis < 7 months from diagnosis were 2.6 times (CI: 1.14-5.95) more likely to reach a yield of 6 × 106 CD34+ cells/kg within the first 1-2 days (p = 0.02). Sixty-seven percent of Cy-G mobilized pts reached a yield of 6 × 106 CD34+/kg in 2 days. Conclusions: CD34+ cell yield following Cy-G mobilization in this retrospective exploratory analysis is comparable to what was reported following plerixafor-G mobilization. We suggest reserving plerixafor for pts with substantial delay between diagnosis and apheresis, and for those failing Cy-G mobilization. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen" @default.
• W2523348044 created "2016-09-30" @default.
• W2523348044 creator A5004358801 @default.
• W2523348044 creator A5004910687 @default.
• W2523348044 creator A5019268804 @default.
• W2523348044 creator A5019799857 @default.
• W2523348044 creator A5023917993 @default.
• W2523348044 creator A5025887498 @default.
• W2523348044 creator A5033267787 @default.
• W2523348044 creator A5043320174 @default.
• W2523348044 creator A5047990108 @default.
• W2523348044 creator A5057798024 @default.
• W2523348044 date "2010-05-20" @default.
• W2523348044 modified "2023-09-26" @default.
• W2523348044 title "Is low-dose cyclophosphamide (Cy) plus G-CSF (G) mobilization as effective as plerixafor plus G in multiple myeloma (MM) patients (pts) who are candidates for tandem autologous transplants (autoT)?" @default.
• W2523348044 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.8142" @default.
• W2523348044 hasPublicationYear "2010" @default.
• W2523348044 type Work @default.
• W2523348044 sameAs 2523348044 @default.
• W2523348044 citedByCount "0" @default.
• W2523348044 crossrefType "journal-article" @default.
• W2523348044 hasAuthorship W2523348044A5004358801 @default.
• W2523348044 hasAuthorship W2523348044A5004910687 @default.
• W2523348044 hasAuthorship W2523348044A5019268804 @default.
• W2523348044 hasAuthorship W2523348044A5019799857 @default.
• W2523348044 hasAuthorship W2523348044A5023917993 @default.
• W2523348044 hasAuthorship W2523348044A5025887498 @default.
• W2523348044 hasAuthorship W2523348044A5033267787 @default.
• W2523348044 hasAuthorship W2523348044A5043320174 @default.
• W2523348044 hasAuthorship W2523348044A5047990108 @default.
• W2523348044 hasAuthorship W2523348044A5057798024 @default.
• W2523348044 hasConcept C10205521 @default.
• W2523348044 hasConcept C126322002 @default.
• W2523348044 hasConcept C126894567 @default.
• W2523348044 hasConcept C129470790 @default.
• W2523348044 hasConcept C13373296 @default.
• W2523348044 hasConcept C141071460 @default.
• W2523348044 hasConcept C170493617 @default.
• W2523348044 hasConcept C2776364478 @default.
• W2523348044 hasConcept C2776738589 @default.
• W2523348044 hasConcept C2777371436 @default.
• W2523348044 hasConcept C2778828106 @default.
• W2523348044 hasConcept C28328180 @default.
• W2523348044 hasConcept C2908647359 @default.
• W2523348044 hasConcept C54355233 @default.
• W2523348044 hasConcept C71924100 @default.
• W2523348044 hasConcept C86803240 @default.
• W2523348044 hasConcept C89560881 @default.
• W2523348044 hasConcept C99454951 @default.
• W2523348044 hasConceptScore W2523348044C10205521 @default.
• W2523348044 hasConceptScore W2523348044C126322002 @default.
• W2523348044 hasConceptScore W2523348044C126894567 @default.
• W2523348044 hasConceptScore W2523348044C129470790 @default.
• W2523348044 hasConceptScore W2523348044C13373296 @default.
• W2523348044 hasConceptScore W2523348044C141071460 @default.
• W2523348044 hasConceptScore W2523348044C170493617 @default.
• W2523348044 hasConceptScore W2523348044C2776364478 @default.
• W2523348044 hasConceptScore W2523348044C2776738589 @default.
• W2523348044 hasConceptScore W2523348044C2777371436 @default.
• W2523348044 hasConceptScore W2523348044C2778828106 @default.
• W2523348044 hasConceptScore W2523348044C28328180 @default.
• W2523348044 hasConceptScore W2523348044C2908647359 @default.
• W2523348044 hasConceptScore W2523348044C54355233 @default.
• W2523348044 hasConceptScore W2523348044C71924100 @default.
• W2523348044 hasConceptScore W2523348044C86803240 @default.
• W2523348044 hasConceptScore W2523348044C89560881 @default.
• W2523348044 hasConceptScore W2523348044C99454951 @default.
• W2523348044 hasIssue "15_suppl" @default.
• W2523348044 hasLocation W25233480441 @default.
• W2523348044 hasOpenAccess W2523348044 @default.
• W2523348044 hasPrimaryLocation W25233480441 @default.
• W2523348044 hasRelatedWork W2022355235 @default.
• W2523348044 hasRelatedWork W2024902315 @default.
• W2523348044 hasRelatedWork W2033563267 @default.
• W2523348044 hasRelatedWork W2156425432 @default.
• W2523348044 hasRelatedWork W2412429546 @default.
• W2523348044 hasRelatedWork W2979715556 @default.
• W2523348044 hasRelatedWork W3176989103 @default.
• W2523348044 hasRelatedWork W3205694180 @default.
• W2523348044 hasRelatedWork W3211271500 @default.
• W2523348044 hasRelatedWork W4210815115 @default.
• W2523348044 hasVolume "28" @default.
• W2523348044 isParatext "false" @default.
• W2523348044 isRetracted "false" @default.
• W2523348044 magId "2523348044" @default.
• W2523348044 workType "article" @default.